# Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer

> **NCT05646550** · PHASE1 · RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 56 (estimated)

## Conditions studied

- Prostate Cancer Recurrent

## Interventions

- **DRUG:** CC-1 Infusion

## Key facts

- **NCT ID:** NCT05646550
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-11
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05646550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05646550, "Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05646550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*